3 Locations

London, Guildford, Plymouth, Windsor

10 Studies

This year, of course.

Limited Availability

Hurry up, register!
You are going to be at the forefront. The reality is that you’re a trail-blazer and it’s far better to be a trail-blazer than last in the queue.
A trial participant

Clinical Trials

Our brains are the key to who we are.

At Re: Cognition Health we are changing the future for those with memory loss and other symptoms of cognitive impairment, through providing education, clinical excellence and access to the most advanced treatments available, worldwide.

This is an exciting time for potential new treatments for Alzheimer’s disease and other causes of mild cognitive impairment (MCI) and dementia. The Re: Cognition Health clinical trials team led by Dr Emer MacSweeney and Dr Stephen Pearson are running a number of international clinical studies providing early access to new and more effective medications in the final phase of development. These medications include those designed to halt or very significantly slow down progression of Alzheimer’s disease and those developed to boost memory and improve other cognitive symptoms. The purpose of a final phase study is to verify, on a large number of people living in different countries the successful results already gained in earlier phase studies. If successful, the pharmaceutical company applies for an international license for the new medication to be available on the market.

One of the good things about the trial is that my father is constantly monitored by experts in the field… They are monitoring everything – all his health issues – so it is very reassuring that we have that extra support.
Family member of trial participant

Eligibility

The only requirement is that you are clinically eligible.

During the first part of the study we undertake some screening tests to confirm you are the right person for the study and more importantly, that the clinical trial and medication provided is appropriate for you.

If you do match for the study, then for an initial predetermined period of time, you will receive either active medication or a placebo. However, in almost all final phase studies, when you have completed this period of time, you will have an opportunity to receive the active medication, as part of an extension study. The pharmaceutical company sponsors all medical care and so there is no cost to you to join one of these studies. You will be carefully monitored throughout the study by our team of cognitive experts, working hard to keep you in the best possible health. The process is voluntary and you can withdraw from a study at any time.

I strongly believe that every patient should have the opportunity to participate in appropriate research which is relevant to her or him
Professor Sally Davies
Chief Medical Officer for England

How to apply for a trial

It’s easy to register.

If you would like to register your interest and arrange a direct phone call with one of our doctors, please fill in the form below or email us at clinician@re-cognitionhealth.com.
You can also phone us on 0203 355 3536 (London and Guildford) and 01752 875604 (Plymouth).

Re:Cognition Health has centres in London, Guildford and Plymouth undertaking the full spectrum of international studies,  for those very mild to more advanced symptoms.

  • Interventional Study
    A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of related drugs in Subjects with Early Alzheimer's Disease.

    A study sponsored by Biogen Ltd. is investigating whether a drug called aducanumab has the potential to be a helpful treatment that slows down disease progression in research participants diagnosed with Alzheimer’s disease, by comparing it to placebo (inactive medication) and evaluating its safety (side effects). Recruiting people with early Alzheimer’s disease who are between 50 and 85 years old.

  • Interventional Study
    A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of a related drug in Early Alzheimer's Disease.

    A study sponsored by Eli Lilly and Company investigating the safety (side effects) and efficacy of a drug for slowing down the progression of Alzheimer’s disease in research participants with a diagnosis of Alzheimer’s disease (AD) or Mild Cognitive Impairment (MCI) due to AD. The investigational drug will be compared to a placebo (inactive medication plus your usual medication). This drug helps reduce the formation of a protein called beta-amyloid that is the major component of plaques found in Alzheimer’s disease. Recruiting people with Alzheimer’s disease or MCI due to AD who are between 55 and 85 years old.

  • Interventional Study
    A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia.

    A study sponsored by Eli Lilly and Company investigating the safety (side effects) and efficacy of a drug for slowing down the progression of Alzheimer’s disease in research participants with a diagnosis of Alzheimer’s disease (AD). The investigational drug will be compared to a placebo (inactive medication plus your usual medication). This drug helps reduce the formation of a protein called beta-amyloid that is the major component of plaques found in Alzheimer’s disease. Recruiting people with Alzheimer’s disease or MCI due to AD who are between 55 and 85 years old.

  • Interventional Study
    Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects With Alzheimer's Disease.

    A study sponsored by Merck Sharpe & Dohme aims to examine the safety and efficacy of Suvorexant (MK-4305) to improve sleep in individuals with Alzheimer's disease (AD). The primary hypothesis for the study is that Suvorexant is superior to placebo in improving insomnia as measured by change from baseline in polysomnography (PSG)-derived total sleep time (TST) at Week 4. Recruiting patients between the ages of 50 and 90 years old with a diagnosis of probable Alzheimer’s and insomnia for at least three months.

  • Interventional Study
    A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects Who Are Asymptomatic At Risk for Developing Alzheimer's Dementia.

    A study sponsored by Janssen to evaluate whether treatment with investigational compound JNJ-54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants who are asymptomatic at risk for developing Alzheimer's dementia. This study is recruiting volunteers aged 60 to 85 Years who are not currently showing symptoms, but are at risk of developing Alzheimer’s disease.

  • Interventional Study
    A Phase 2, Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Alzheimer’s Disease.

    A study sponsored by Boehringer Ingleheim to evaluate the safety and effectiveness of the investigational compound BI 409306 in patients with prodromal (early stage) Alzheimer’s disease, at different dose levels. This study is recruiting volunteers aged 55 years and older.

  • Interventional Study
    A Phase 2, Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease.

    A study sponsored by Boehringer Ingleheim to evaluate the safety and effectiveness of the investigational compound BI 409306 in patients with early signs of dementia of Alzheimer’s type, at different dose levels. This study is recruiting volunteers aged 55 years and older.

  • Interventional Study
    A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine: A Randomized, Double-blind, Placebo-controlled Parallel Group Study.

    A study sponsored by CoLucid to evaluate the efficacy of a drug at three different doses compared to placebo (an inactive medication) for reducing migraine headache pain and the Most Bothersome Symptom, as identified by the individual from the associated symptoms of nausea, phonophobia and photophobia. Recruiting patients 18 years old and over with a history of 3 – 8 migraine attacks per month.

  • Interventional Study
    A Randomized, Double-blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine.

    A study sponsored by vTv Therapeutics to evaluate the efficacy and safety of Azeliragon in patients with mild Alzheimer's disease. Patients will receive either Azeliragon or placebo with a patient's participation lasting approximately 18 months. Recruiting patients aged 50 years and older with a diagnosis of probable Alzheimer’s disease.

  • Interventional Study
    A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB).

    A study sponsored by Axovant, to assess the effects of RVT-101 compared with placebo (an inactive medication) for the treatment of Dementia with Lewy Bodies. Recruiting patients between 50 and 85 years old.

  • Interventional Study
    A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of a drug in Subjects With Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease.

    A study sponsored by Merck Sharp and Dohme Corp. investigating the efficacy and safety of an investigational drug compared with placebo (inactive medication plus your usual medication) in research participants with prodromal Alzheimer’s Disease. Recruiting people with prodromal Alzheimer’s disease who are between 50 to 85 years old.

Available Studies

There is a study for you.

Below are further details of the international studies, taking place at Re:Cognition Health Centres, for which we are enrolling, currently:

Register

Email us at clinician@re-cognitionhealth.com. You can also phone us on 0203 355 3536 (London and Guildford) and 01752 875604 (Plymouth).

Do you have a diagnosis of Alzheimer's Disease or Mild Cognitive Impairment (MCI)?

Have any relatives or friends expressed concerns about your short-term memory?

Do you have a pacemaker?

Do you have insomnia?

Are you currently taking any related medication?

Bipolar disorder or schizophrenia?

Bleeding disorder or taking any anticoagulant medicine (except asprine)

Cancer (except skin cancer) in the past 5 years

Congestive heart failure in the past 5 years

Heart attack or myocardial infraction in the past 12 months

HIV or AIDS

Seizures in the past 10 years

Stroke or TIA (transient ischemic attack) in the past 12 months